BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 34870679)

  • 1. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
    Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
    JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of an intervention to implement provision of opioid use disorder medication among patients with and without co-occurring substance use disorders.
    Frost MC; Malte CA; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    J Subst Use Addict Treat; 2023 Dec; 155():209175. PubMed ID: 37751798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating Opioid Use Disorder Treatment Into Primary Care Settings.
    Austin EJ; Chen J; Briggs ES; Ferro L; Barry P; Heald A; Merrill JO; Curran GM; Saxon AJ; Fortney JC; Ratzliff AD; Williams EC
    JAMA Netw Open; 2023 Aug; 6(8):e2328627. PubMed ID: 37566414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
    Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
    Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
    J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention.
    Gustavson AM; Kenny ME; Wisdom JP; Salameh HA; Ackland PE; Gordon AJ; Hagedorn HJ
    Addict Sci Clin Pract; 2021 Aug; 16(1):51. PubMed ID: 34362445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
    Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
    J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities.
    Hagedorn HJ; Gustavson AM; Ackland PE; Bangerter A; Bounthavong M; Clothier B; Harris AHS; Kenny ME; Noorbaloochi S; Salameh HA; Gordon AJ
    J Gen Intern Med; 2022 Nov; 37(14):3594-3602. PubMed ID: 34981352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
    Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
    Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder.
    Beckman KL; Williams EC; Hebert P; Hawkins EJ; Littman AJ; Lehavot K
    J Subst Abuse Treat; 2022 Aug; 139():108775. PubMed ID: 35317959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
    Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes.
    Bovell-Ammon BJ; Yan S; Dunn D; Evans EA; Friedmann PD; Walley AY; LaRochelle MR
    JAMA Netw Open; 2024 Mar; 7(3):e242732. PubMed ID: 38497959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
    Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
    JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.